Symeres Acquires DGr Pharma
CRDMO Symeres has acquired DGr Pharma, expanding its capabilities with DGr Pharma’s regulatory and consultancy expertise to provide more comprehensive drug development services.
Symeres, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has acquired DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments.
Founded in 2018 and based in the Netherlands, DGr Pharma specialises in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. Its core services include chemical-pharmaceutical, non-clinical, and clinical development planning, quality assurance, and regulatory submissions. DGr Pharma has deep expertise in small and large molecules, including antibodies, ADCs, and oligonucleotides. With a reputation for scientific rigor, DGr Pharma adds significant regulatory depth to the Symeres portfolio, enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development.
DGr Pharma’s pharmacokinetic data analysis services operate under Good Clinical Practice (GCP) and Good Laboratory Practice (GLP), expertise that aligns with Symeres’ integrated offering, including ADME. The GLP status enhances data quality and regulatory readiness, giving Symeres’ clients a more efficient and reliable path to IND submission.
Guillaume Jetten, CEO of Symeres, commented: “This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. The company enhances our scientific capabilities, allowing us to better support our clients’ evolving needs and reinforce Symeres’ position as a partner of choice in the global biopharma market."
Kees Groen, Founder and CEO of DGr Pharma, added: "This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres’ commitment to high-quality science, long-term relationships, and entrepreneurial ambition, and we look forward to being part of the next phase of growth."
